Tara M. Robinson

Senior Medical Director
BioMarin Pharmaceuticals Inc.
Novato, California, United States

Presentation(s):

• PB0229 - Results from the Taiwanese cohort in GENEr8-1: bleeding rates, factor VIII usage, quality of life and safety in severe Hemophilia A patients after gene therapy

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 30.1 - Seven-year follow-up of valoctocogene roxaparvovec gene therapy for haemophilia A

  Monday, June 24, 2024
  09:30 – 09:45 ICT

• OC 30.2 - Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1

  Monday, June 24, 2024
  09:45 – 10:00 ICT

• PB0558 - Efficacy, Safety and Quality of Life Three Years After Gene Transfer With Valoctocogene Roxaparvovec in a Brazilian Cohort

  Monday, June 24, 2024
  13:45 – 14:45 ICT